IR HOME NEWS & EVENTS OVERVIEW PRESS RELEASES EVENTS & PRESENTATIONS STOCK INFORMATION OVERVIEW HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE FINANCIALS & FILINGS OVERVIEW SEC FILINGS CORPORATE GOVERNANCE OVERVIEW LEADERSHIP BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT IR IR HOME NEWS & EVENTS OVERVIEW PRESS RELEASES EVENTS & PRESENTATIONS STOCK INFORMATION OVERVIEW HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE FINANCIALS & FILINGS OVERVIEW SEC FILINGS CORPORATE GOVERNANCE OVERVIEW LEADERSHIP BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT IR Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study Read more about Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study Ardelyx to Present at the Piper Jaffray 31st Annual Healthcare Conference Read more about Ardelyx to Present at the Piper Jaffray 31st Annual Healthcare Conference Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements Read more about Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements Ardelyx Announces Presentation at Kidney Week 2019 Read more about Ardelyx Announces Presentation at Kidney Week 2019 Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights Read more about Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights Ardelyx to Host Analyst Day in New York Read more about Ardelyx to Host Analyst Day in New York Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference Read more about Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation Read more about Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment Read more about Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study Read more about Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study Pagination First page « First Previous page ‹ Previous … Page 12 Page 13 Page 14 Page 15 Current page 16 Page 17 Page 18 Page 19 Page 20 … Next page Next › Last page Last » Subscribe to FAQs Email Alerts Connect
Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study Read more about Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study
Ardelyx to Present at the Piper Jaffray 31st Annual Healthcare Conference Read more about Ardelyx to Present at the Piper Jaffray 31st Annual Healthcare Conference
Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements Read more about Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements
Ardelyx Announces Presentation at Kidney Week 2019 Read more about Ardelyx Announces Presentation at Kidney Week 2019
Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights Read more about Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights
Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference Read more about Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference
Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation Read more about Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation
Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment Read more about Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment
Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study Read more about Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study